Literature DB >> 10867960

Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

B A Johnson1, N Ait-Daoud.   

Abstract

Preclinical studies have exploded our knowledge about the behavioral and biological underpinnings of alcoholism. These studies suggest that certain neurotransmitters, particularly those interacting with the opioid, N-methyl-D-aspartate, and monoamine systems, may play a critical role in the expression of alcohol-drinking and other behaviors associated with its abuse liability. Built upon this foundation, important advances have been made in the development of therapeutic medications for the treatment of alcoholism. Of the medications reviewed, acamprosate's potential appears to be the most widely established. In the USA, naltrexone was approved by the Food and Drug Administration in 1995 for the treatment of alcoholism; however, the results of some studies have been less encouraging. Naltrexone's reliance on high compliance rates for efficacy may, eventually, limit its potential in clinical settings offering generic treatment for alcoholism. The relative paucity of dose-response studies on naltrexone's effects in treating alcoholics is an important gap in the literature. Recent data from a large clinical trial suggests that ondansetron, a serotonin3 antagonist, offers new hope for the treatment of early onset alcoholics; a type of alcoholism most difficult to manage with psychosocial measures alone. Different subtypes of alcoholic may, therefore, have varying treatment responses to serotonergic agents. Matching subtypes of alcoholic to effective treatment medications based upon their different biologies remains an important therapeutic goal. Combinations of effective pharmacological agents need exploration as they may prove to be synergistic, and could shepherd in a new era of treatments aimed at multiple neurotransmitter targets associated with the alcoholism disease. The coming decade promises more powerful tools for characterizing drug effects on alcohol drinking, thereby closing the gap between animal models of addiction and the human condition.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10867960     DOI: 10.1007/s002130000371

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

Review 1.  Addiction and the brain: the role of neurotransmitters in the cause and treatment of drug dependence.

Authors:  D M Tomkins; E M Sellers
Journal:  CMAJ       Date:  2001-03-20       Impact factor: 8.262

Review 2.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

3.  Development of a two-step route to 3-PBC and βCCt, two agents active against alcohol self-administration in rodent and primate models.

Authors:  Ojas A Namjoshi; Angelica Gryboski; German O Fonseca; Michael L Van Linn; Zhi-jian Wang; Jeffrey R Deschamps; James M Cook
Journal:  J Org Chem       Date:  2011-05-04       Impact factor: 4.354

4.  Can serotonin transporter genotype predict serotonergic function, chronicity, and severity of drinking?

Authors:  Bankole A Johnson; Martin A Javors; John D Roache; Chamindi Seneviratne; Susan E Bergeson; Nassima Ait-Daoud; Michael A Dawes; Jennie Z Ma
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-08-19       Impact factor: 5.067

5.  Polymorphisms in the NMDA subunit 2B are not associated with alcohol dependence and alcohol withdrawal-induced seizures and delirium tremens.

Authors:  Andre Tadic; Norbert Dahmen; Armin Szegedi; Dan Rujescu; Ina Giegling; Gabriele Koller; Ion Anghelescu; Christoph Fehr; Christoph Klawe; Ullrich W Preuss; Thomas Sander; Mohammad R Toliat; Peter Singer; Brigitta Bondy; Michael Soyka
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2004-11-19       Impact factor: 5.270

6.  Neurosteroid modulators of GABA(A) receptors differentially modulate Ethanol intake patterns in male C57BL/6J mice.

Authors:  Matthew M Ford; Jeffrey D Nickel; Tamara J Phillips; Deborah A Finn
Journal:  Alcohol Clin Exp Res       Date:  2005-09       Impact factor: 3.455

7.  Prediction of serotonergic treatment efficacy using age of onset and Type A/B typologies of alcoholism.

Authors:  John D Roache; Yanmei Wang; Nassima Ait-Daoud; Bankole A Johnson
Journal:  Alcohol Clin Exp Res       Date:  2008-06-28       Impact factor: 3.455

8.  The Role of Glial Cells in Drug Abuse.

Authors:  Jose Javier Miguel-Hidalgo
Journal:  Curr Drug Abuse Rev       Date:  2009

9.  Preliminary data on the association among the serotonin transporter polymorphism, subjective alcohol experiences, and drinking behavior.

Authors:  William R Corbin; Kim Fromme; Susan E Bergeson
Journal:  J Stud Alcohol       Date:  2006-01

10.  The sigma-receptor antagonist BD-1063 decreases ethanol intake and reinforcement in animal models of excessive drinking.

Authors:  Valentina Sabino; Pietro Cottone; Yu Zhao; Malliga R Iyer; Luca Steardo; Luca Steardo; Kenner C Rice; Bruno Conti; George F Koob; Eric P Zorrilla
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.